Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

EPO Application Posted today - FCRN ANTIBODIES AND METHODS OF USE THEREOF - 2.28.2019 (Original date)

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190228&DB=EPODOC&locale=en_EP&CC=AU&NR=2017301915A1&KC=A1&ND=4&pageNumber=2